Canada markets closed
  • S&P/TSX

    18,060.26
    -163.28 (-0.90%)
     
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • DOW

    30,932.37
    -469.64 (-1.50%)
     
  • CAD/USD

    0.7851
    -0.0088 (-1.11%)
     
  • CRUDE OIL

    61.66
    -1.87 (-2.94%)
     
  • BTC-CAD

    60,571.45
    +257.80 (+0.43%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • GOLD FUTURES

    1,733.00
    -42.40 (-2.39%)
     
  • RUSSELL 2000

    2,201.05
    +0.88 (+0.04%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • NASDAQ

    13,192.35
    +72.92 (+0.56%)
     
  • VOLATILITY

    27.95
    -0.94 (-3.25%)
     
  • FTSE

    6,483.43
    -168.53 (-2.53%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • CAD/EUR

    0.6499
    -0.0013 (-0.20%)
     

BSX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021

·2 min read

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/bsx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (2) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/bsx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Boston Scientific you have until February 3, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005055/en/

Contacts

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com